Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) released its earnings results on Monday. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01, Zacks reports.
Cardiol Therapeutics Stock Performance
NASDAQ:CRDL traded down $0.10 during mid-day trading on Friday, hitting $0.81. The company's stock had a trading volume of 226,832 shares, compared to its average volume of 384,271. The business's fifty day moving average is $1.17 and its two-hundred day moving average is $1.49. The stock has a market cap of $66.91 million, a price-to-earnings ratio of -2.08 and a beta of 0.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49. Cardiol Therapeutics has a 1 year low of $0.81 and a 1 year high of $3.12.
Analysts Set New Price Targets
CRDL has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research note on Monday, February 24th. RODMAN&RENSHAW raised Cardiol Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on Cardiol Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $7.00 price objective on the stock. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $8.40.
Get Our Latest Report on Cardiol Therapeutics
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Stories
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
